Get the Stockscreener App
18.09
4.27%
0.74
After Hours:
17.84
-0.25
-1.38%
Instil Bio Inc stock is traded at $18.09, with a volume of 56,278.
It is up +4.27% in the last 24 hours and down -5.63% over the past month.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
See More
Previous Close:
$17.35
Open:
$17.64
24h Volume:
56,278
Relative Volume:
0.63
Market Cap:
$118.05M
Revenue:
-
Net Income/Loss:
$-156.09M
P/E Ratio:
-0.7538
EPS:
-24
Net Cash Flow:
$-102.69M
1W Performance:
+0.22%
1M Performance:
-5.63%
6M Performance:
-61.06%
1Y Performance:
+50.12%
1-Day Range:
$17.31
$18.54
1-Week Range:
$15.66
$20.27
52-Week Range:
$9.62
$92.00
Instil Bio Inc Stock (TIL) Company Profile
Name
Instil Bio Inc
Sector
Industry
Phone
(972) 499-3350
Address
3963 MAPLE AVENUE, DALLAS
Compare TIL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TIL
Instil Bio Inc
|
18.09 | 118.05M | 0 | -156.09M | -102.69M | -24.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
495.42 | 127.22B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
689.50 | 75.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.45 | 35.94B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.43 | 31.38B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.84 | 26.84B | 3.32B | -860.46M | -1.04B | -8.32 |
Instil Bio Inc Stock (TIL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-25 | Upgrade | Jefferies | Hold → Buy |
| Nov-04-24 | Initiated | JMP Securities | Mkt Perform |
| Apr-12-24 | Downgrade | Jefferies | Buy → Hold |
| Nov-01-22 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-01-22 | Downgrade | Truist | Buy → Hold |
| Aug-13-21 | Initiated | Robert W. Baird | Outperform |
| Apr-13-21 | Initiated | Cowen | Outperform |
| Apr-13-21 | Initiated | Morgan Stanley | Equal-Weight |
| Apr-13-21 | Initiated | Truist | Buy |
View All
Instil Bio Inc Stock (TIL) Latest News
Instil Bio, Inc. SEC 10-K Report - TradingView
Instil Bio Reports 2024 Financial Results and Outlook - TipRanks
Instil Bio reports Q4 adjusted EPS ($1.08) vs. ($1.26) last year - TipRanks
Instil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - The Manila Times
When (TIL) Moves Investors should Listen - Stock Traders Daily
Institutions along with private equity firms who hold considerable shares inInstil Bio, Inc. (NASDAQ:TIL) come under pressure; lose 12% of holdings value - Simply Wall St
Instil Bio: Time To Hop On The Summit Wave? (NASDAQ:TIL) - Seeking Alpha
(TIL) Technical Data - Stock Traders Daily
Private equity firms who hold 38% of Instil Bio, Inc. (NASDAQ:TIL) gained 34%, institutions profited as well - Yahoo Finance
(TIL) Investment Analysis and Advice - Stock Traders Daily
(TIL) Investment Report - Stock Traders Daily
What Makes Instil Bio (TIL) a New Buy Stock - MSN
Instil Bio Announces Clinical Progress in China for - GlobeNewswire
Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody - Marketscreener.com
Instil Bio Advances Lung Cancer Treatment: First Patient Dosed in Phase 1b/2 Trial of Novel PD-L1xVEGF Therapy - StockTitan
Instil Bio Stock Soars After Jefferies Upgrade On 'Early Mover' Cancer Drug Candidate: Retail Jubilant - MSN
Jefferies Upgrades Instil Bio (TIL) - MSN
Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside - Benzinga
How To Trade (TIL) - Stock Traders Daily
Instil Bio Secures Loan to Refinance Facility - MSN
Long Term Trading Analysis for (TIL) - Stock Traders Daily
Trend Tracker for (TIL) - Stock Traders Daily
Instil Bio’s Strategic Shift To SYN-2510: A Speculative ‘Buy’ Opportunity (NASDAQ:TIL) - Seeking Alpha
(TIL) Trading Report - Stock Traders Daily
Merck Inks $3.3B Licensing Deal With Chinese Biotech for Cancer Therapy - Yahoo Finance
Instil Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
Instil Bio Secures Global Rights to PD-L1xVEGF Drug, Reports $122.9M Cash Position | TIL Stock News - StockTitan
2 Stocks Up Over 700% in 2024 That Could Soar Even Further - AOL
JMP Securities initiates Instil Bio shares at Market Perform on public offering - Investing.com Australia
Instil Bio, Inc.'s (NASDAQ:TIL) stock price dropped 18% last week; private equity firms would not be happy - Simply Wall St
Up Over 600% in 2024, Can Summit Therapeutics Stock Keep Rising? - The Motley Fool
Summit Stock Skyrockets Nearly 700% YTD: Time to Sell or Hold? - Nasdaq
Analysis of Curative Ventures V LLC's Strategic Reduction in Instil Bio Inc - GuruFocus.com
(TIL) Long Term Investment Analysis - Stock Traders Daily
Baird maintains price target on Instil Bio stock, stays upbeat - Investing.com
5 Top NASDAQ Biotech Stocks of 2024 - Nasdaq
FDA Oncology Approvals Accelerate as Global Cancer Rates Set to Climb 77% - Baystreet.ca
Instil Bio Stock Skyrockets 641% in One Week: Here's Why - MSN
BOXER CAPITAL, LLC Acquires New Stake in Instil Bio Inc - GuruFocus.com
Perceptive Advisors LLC Acquires New Stake in Instil Bio Inc - GuruFocus.com
Baird sees Instil Bio stock upside on promising SYN-2510 clinical data - Investing.com
Fantastic Fest 2024: Clowns Rule at Texas’ No-Joke Genre Event Set to Debut ‘Terrifier 3,’ ‘V/H/S Beyond,’ and More - IndieWire
B. Riley Analysts Decrease Earnings Estimates for Inspired Entertainment, Inc. (NASDAQ:INSE) - Defense World
The time has not yet come to remove your chips from the table: Instil Bio Inc (TIL) - SETE News
Instil Bio Inc Stock (TIL) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):